Crown Bioscience and NEXT Oncology Cement Partnership Extension
Crown Bioscience and NEXT Oncology Cement Partnership Extension
Share
Through this extended agreement, Crown Bioscience reaffirms its exclusive rights to provide services based on patient samples sourced from NEXT Oncology's industry-leading global clinical trial network. This collaboration underscores Crown Bioscience's commitment to providing the most clinically relevant PDX and organoid models and solutions for translational oncology research.
"We are thrilled to continue our exclusive partnership with NEXT Oncology," said John Gu, CEO of Crown Bioscience. "NEXT Oncology is globally recognized for its pioneering work in Phase I clinical oncology trials. Extending this partnership allows us to broaden our portfolio and strengthen our position as a leader in translational oncology platforms and integrated solutions. Our combined expertise and global reach will ensure rapid and scalable access to groundbreaking cancer models for our biopharma partners."
'NEXT Oncology is excited to continue our strong partnership with Crown Bioscience,' said Dr. Anthony Tolcher, CEO of NEXT Oncology. 'Together, we will continue to develop new and highly relevant patient models that Crown's biopharma partners can utilize to advance their translational oncology programs. Our combined efforts continue to support both companies' missions to help cancer patients receive the most advanced medicines possible.'
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world's largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit http://www.crownbio.com.
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Factbox-How China tightened its grip over its rare earth sector
(Reuters) -When China restricted rare earth exports to Japan in 2010 during a diplomatic spat, a wild west domestic industry undermined Beijing with rampant smuggling. In a sharp shift that reflects how China has massively tightened control over the sector since then, when it imposed new restrictions in April this year, automakers worldwide faced shortages within two months leading some to pause production. Through consolidation and quotas, Beijing has turned a once-unruly sector, responsible for 90% of rare earth processing capacity, into a powerful source of diplomatic leverage. Here is a summary of how the world's number one rare earth producer has tightened its grip over the industry. CONSOLIDATION When China began its crackdown on the sector some fifteen years ago, there were hundreds of miners and processors. By 2013 ten producers controlled almost all mining. Today, there are just two state-owned giants: China Rare Earth Group and China Northern Rare Earth Group High-Tech. The decade-plus process of consolidation gave Beijing greater oversight while also curbing some of the environmental damage caused by illegal and reckless mining, according to David Abraham, affiliate professor at Boise State University, in Idaho. In the past an illegal supply chain of rogue miners delivered ore to unauthorised separation facilities, with the finished products then disguised and shipped abroad. Roughly 40,000 metric tons of rare earth oxides were estimated to have been smuggled overseas in 2014, half as much again as official exports. Magnet makers, however, have not consolidated in the same way as the upstream mining and refining sector, with dozens of producers and processors across China, including JL Mag Rare-Earth and Ningbo Yunsheng. However, China introduced a tracking system for its rare earth magnet sector from June, requiring companies to submit information including customer details and transaction volumes. It ultimately aims to track the entire supply chain. QUOTAS In conjunction with consolidation, China has also used its production quota system, introduced in 2006, to control supply. The quotas cover mining, smelting and separation. Typically issued twice a year, they are widely monitored as a barometer for global supply. Beijing has gradually narrowed access to quotas and in 2024, only the two state-owned groups were eligible, compared to six previously. China has dramatically slowed down supply growth from 2024 when the total mining output quota grew only 5.9% year-on-year, versus an annual rise of 21.4% in 2023. Analysts and traders expect mining output quotas this year to either stay flat or rise by up to 5% from 2024's level. Beijing also restricts exports of technology. The tools and means to extract and separate rare earths have long been banned. In late 2023 it extended that ban to the technology used to make rare earth magnets.
Yahoo
an hour ago
- Yahoo
Japan must reduce reliance on US trade, opposition head says
By Leika Kihara and Takaya Yamaguchi TOKYO (Reuters) -Japan must diversify trade ties beyond the U.S. market to mitigate risks and focus on partnerships with countries favouring free trade, Hirofumi Yoshimura, co-representative of the opposition Japan Innovation Party, said on Monday. Tokyo should seek a "win-win" situation in trade negotiations, however, tariffs imposed by President Donald Trump show how the U.S. is a country risk for Japan - or a source of uncertainty that could hurt its economy, Yoshimura said. "Japan should expand trade ties with countries that focus on free trade," such as Europe, and leave itself more options to protect its economy, he told Reuters in an interview. "Instead of standing on just one, big pillar like the U.S., Japan should stand on, say, five to 10 smaller pillars. That's a better approach to avoid its roof from falling off." The remarks came as Japan faces the risk of sustained, steep U.S. tariffs after stalled trade talks led to criticism by Trump that Japan was engaging in "unfair" automobile trade. The views of small, opposition parties such as the Japan Innovation Party could gain importance after an upper house election on July 20, where Prime Minister Shigeru Ishiba's ruling Liberal Democratic Party (LDP) faces an uphill battle. Recent media polls including one by the Yomiuri newspaper showed the LDP and its coalition partner Komeito may lose their majority in the upper house - an outcome analysts say could force Ishiba to step down or seek an alliance partner. The LDP-Komeito ruling camp is already a minority coalition in the lower house, forcing Ishiba to seek the cooperation of opposition parties to pass some bills through parliament. Ishiba maintained his hard-line stance on trade talks with Washington in a television programme on Sunday, saying Japan will continue to demand the elimination of U.S. automobile tariffs and "won't make concessions easily." U.S. tariffs would add to woes for Japan's economy, which contracted in the first quarter as consumption took a hit from rising living costs. Yoshimura said Japan must focus on deregulation to revitalise the economy and reforms to rein in its ballooning social welfare costs that are straining its finances. On monetary policy, Yoshimura said the Bank of Japan (BOJ) should continue to phase out its ultra-loose policy but at a slow, cautious pace. "Japan has a huge public debt and relies on debt issuance in guiding policy," he said. "In light of this situation, the BOJ must tread carefully in raising interest rates." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Bond Vigilantes Give ‘Worse Than Greece' Japan A Reprieve
getty Global bond markets can breathe a little easier following Japan's successful sales of 30-year debt on Thursday. A low bar, perhaps, but then Japanese government bond (JGB) auctions over the last six weeks have tended to make global headlines for all the wrong reasons. Weak demand for a 20-year JGB sale in mid-May rocked markets everywhere. That auction attracted the fewest bids since 2012. The fact it happened at a moment when U.S. yields were spiking higher thanks to President Donald Trump's tariffs amplified the reaction in markets. By some measures, it was the sloppiest Japanese sale since 1987. The 'tail,' the gap between the average and lowest-accepted price, was the widest in 38 years. Japan's sale of 40-year bonds later that month didn't exactly pull in the bids either. Clearly, Prime Minister Shigeru Ishiba didn't help things by saying in May that Japan's deteriorating finances are 'worse than Greece.' Talk about putting Japan in global headlines for all the wrong reasons. Hence the relief this week. The so-called bid-to-cover ratio, a key barometer of demand, was the best since February — 3.58. Last month, the Ministry of Finance announced plans to curtail the size of auctions given the risk of more flops. It reduced its offerings of 20-, 30-, and 40-year debt by about $22 billion from now until March 2026. To further smooth things over, the Bank of Japan is scaling back its 'quantitative tightening' ambitions. Yet, a bull market in uncertainty plagues not just the JGB and U.S. Treasury markets but debt bourses everywhere. That's because no one knows whether Trump's trade war is winding down or about to kick into a higher gear. On July 9, the globe will wait with bated breath for Trump's decision on 'reciprocal' tariffs. That's the day his delay on imposing huge import taxes on foes and friends alike expires. Much of the turmoil in debt markets is related to worries that tariffs will send global inflation sharply higher Tokyo is already grappling with a 3.7% year-on-year inflation rate, nearly double the Bank of Japan's 2% target. Anything that exacerbates inflation will put more pressure on the BOJ to continue tightening. Yet with growth contracting 0.2% in the first quarter year on year — and likely to shrink further in the second — big hiking rates could do more harm than good. For all the talk of stagflation in the U.S., Japan may be even more susceptible to this most dreaded of dilemmas. If so, the odds of increased government spending rise exponentially. That could put upward pressure on bond yields, boosting borrowing costs for the developed nation with the biggest debt burden. There's an argument that JGBs are less vulnerable than peers because about 88% of outstanding issues are held domestically. This gives rise to a mutually-assured destruction dynamic. If JGB yields rose to 2% or 3%, banks, insurance companies, pension funds, endowments, the postal system and the growing ranks of retirees would suffer painful losses. So, the collective incentive is to hold onto debt issues rather than selling. Yet with Trump mulling new shocks to the global financial system, the JGB market is decidedly in harm's way. So is, by extension, the so-called 'yen carry trade.' A quarter century of zero rates has made Japan into the top creditor nation. It became common practice for investment funds everywhere to borrow cheaply in yen to bet on higher-yielding assets around the globe. That's why this trade going awry has been known to blow up hedge funds here and there. The good news is that Japan's debt auctions are now attracting enough demand to calm nerves — and placate the bond vigilantes. The bad news is that all bets could be off if Trump decides to make trade wars great again.
